The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Accord Healthcare’s Henlius-partnered Hetronifly ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

UK MHRA approves Accord Healthcare’s anti-PD-1 monoclonal antibody, serplulimab to treat aggressive form of SCLC: United Kingdom Monday, June 23, 2025, 09:00 Hrs [IST] The Medic ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults ...

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

SCLC represents approximately 15% of all lung cancer cases, and 70% of these cases are extensive-stage disease, according to Paz-Ares. For these patients, SOC treatment is comprised of induction ...

ALEXANDRIA, Va. — Results from a global phase 3 clinical trial found that maintenance therapy with a combination of lurbinectedin and atezolizumab helped some patients with extensive-stage small cell ...

SCLC is a highly aggressive form of lung cancer. 3 LS-SCLC typically recurs and progresses rapidly, despite initial response to standard-of-care chemotherapy and radiotherapy. 2,4 The prognosis ...

SCLC is a highly aggressive form of lung cancer. 3 LS-SCLC typically recurs and progresses rapidly, despite initial response to standard-of-care chemotherapy and radiotherapy. 2,4 The prognosis for LS ...

The distant form, where SCLC has spread to a distant part of your body, is the most deadly. Its 5-year survival rate is only 3%. But nearly 70% of people with SCLC have this form when they’re ...

SCLC is a notoriously aggressive form of cancer. A 2021 analysis of the US Surveillance, Epidemiology, and End Results (SEER) database found that between 1983 and 2012, ...